| Date | Title | Description |
| 21.01.2014 | Teva Expands CNS Specialty Business with Acquisition of NuPathe | JERUSALEM–(BUSINESS WIRE)–Jan. 21, 2014– Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq:PATH) for $3.65 per share in cash, o... |
| 17.01.2013 | NuPathe gets FDA approval for migraine patch | The approval for the Zecuity came more than a year after the Conshohocken, Pennsylvania-based company’s initial submission was met with a complete response letter from the U.S. Food and Drug Administration that required the company to do ad... |
| 13.11.2012 | Penn (still) has high rate of alumni entrepreneurs leaving the region: report [VC Roundup] | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pa... |
| 30.10.2012 | Safeguard Scientifics sees lower valuations, bigger 3Q loss [VC Roundup] | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pa... |
| 30.10.2012 | Safeguard Scientifics sees lower valuations, bigger 3Q loss [VC Roundup] | Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pa... |
| 09.10.2012 | Migraine patch developer reduces workforce in cost cutting measure | Anido replaced Jane Hollingsworth, who started the company in 2006, and had previously suceeded her at Auxilium Pharmaceuticals (NASDAQ: AUXL).
In addition to the job cuts, the company is also delaying the fling of an investigational new dr... |
| 26.09.2012 | Migraine pain patch developer NuPathe raises $28M in private stock sale | Armando Anido, the CEO of the company who replaced Jane Hollingsworth earlier this year, said in a statement that it would also look for a commercial partner.
“We believe this financing, combined with the cost containment measures we expect... |
| 26.09.2012 | Abiomed: Medicare coverage decision unlikely for Impella | Wall Street Beat | Abiomed (NSDQ:ABMD) said it doesn’t believe that the Centers for Medicare & Medicaid Services is likely to bestow a national coverage decision for its Impella heart pump.
"We believe, after recent communication and review of all co... |
| 26.07.2012 | Migraine patch developer’s new CEO maps out priorities for commercialization | “My number one priority is cash. We need to have sufficient resources from a money standpoint to execute the launch of the product,” Anido said.
Jane Hollingsworth, who resigned Wednesday, is staying with the company as a consultant and lev... |
| 25.07.2012 | Biopharmaceutical firm NuPathe co-founder and CEO exits, enter former Auxilium head | Incoming CEO and board member Armando Anido has 30 years of experience in the pharmaceutical industry most recently as president and CEO of Auxilium Pharmaceuticals. During his six-year tenure there he helped grow market capitalization from... |
| 16.07.2012 | Migraine patch application resubmitted for FDA approval | Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA.
“With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity ... |
| 19.12.2011 | NuPathe CEO on leading a startup and the challenge of shifting fundraising dynamics | Six years after NuPathe’s launch to develop drugs for central nervous system disorders from migraines to schizophrenia to Parkinson’s disease, the company is in the process of refiling its first New Drug Application for its Zelrix migraine ... |
| 29.11.2011 | NB Therapeutics raising $1 million to fund nail fungus therapy | Iontophoresis involves using electric currents to improve drug delivery through the skin and nails, a method the company says improves drug delivery since it can facilitate delivery of high concentrations of a medication in a single dose an... |
| 15.11.2011 | NuPathe to resubmit migraine patch for approval in 2012 | Migraine headaches affect about 31 million adults in the United States. Symptoms include moderate to severe headache pain, nausea and vomiting, photophobia, or abnormal sensitivity to light, and phonophobia, or abnormal sensitivity to sound... |
| 21.02.2011 | New Pittsburgh venture fund eyes Cleveland location | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 18.09.2009 | Friday Q&A: Jane Hollingsworth of NuPathe on Zelrix, migraines and more | Updated 9/18/09 @ 2:42 p.m. Name in title
When Jane Hollingsworth takes a pill to help fight a headache, she might get nauseous or sicker still.
More than half of American adults suffer similarly, she says, which is a bear of a nuisance for... |
| 07.08.2009 | Friday Q&A: Russell Greig of GlaxoSmithKline’s SR One | Russell Greig has come a long way.
The 57-year-old Scotsman, who still carries that signature and recognizable accent, rode a Fulbright scholarship and a nearly three-decades-long career with pharmaceutical giant GlaxoSmithKline to head SR ... |
| - | NuPathe CEO on leading a startup and the challenge of shifting fundraising dynamics | Jane Hollingsworth, the CEO of NuPathe (NASDAQ:PATH), tends to stand out around Philadelphia. It’s not just because she has founded two drug development companies — Auxilium Pharmaceuticals (NASDAQ:AUXL) and NuPathe — and taken them public.... |
| - | Migraine patch developer reduces workforce in cost cutting measure | The new CEO of NuPathe (NASDAQ:PATH) followed through on his pledge to cut costs at the biopharmaceutical startup by reducing its workforce by half, according to documents filed with the Securities and Exchange Commission.
The cuts, which w... |
| - | Migraine patch developer’s new CEO maps out priorities for commercialization | The leadership change at NuPathe (NASDAQ:PATH) has ushered in a CEO with the sales and marketing background to bring its first product — a migraine patch — to market, a move that is likely to loosen up the purse strings of conservative inve... |
| - | NB Therapeutics raising $1 million to fund nail fungus therapy | Nitric BioTheraputics, a biopharmaceutical and medical device company, is raising $1 million to fund clinical trials of its drug-delivery therapy for onychomycosis, a type of nail fungus, according to the CEO of the company, Frank McCaney.
... |
| - | NuPathe gets FDA approval for migraine patch | Migraine sufferers (and no doubt some investors) will be feeling some relief tonight after NuPathe (NASDAQ: PATH) secured approval from the U.S. Food and Drug Administration for its lead product — the first skin patch to deliver sumatriptan... |
| - | Biopharmaceutical firm NuPathe co-founder and CEO exits, enter former Auxilium head | Biopharmaceutical firm NuPathe’s (NASDAQ:PATH) CEO Jane Hollingsworth has resigned as CEO and board member of the company she co-founded more than six years ago. She has been replaced by the former CEO of Auxilium Pharmaceuticals (NASDAQ:AU... |
| - | Migraine patch application resubmitted for FDA approval | NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration after resolving issues raised in a complete response letter last year.
The Zelrix tra... |
| - | Migraine pain patch developer NuPathe raises $28M in private stock sale | In the run up to the commercialization of its migraine pain patch drug delivery system, NuPathe (NASDAQ: PATH), a specialty pharmaceutical company, has raised $28 million in a private stock sale.
The U.S. Food and Drug Administration has se... |
| - | NuPathe to resubmit migraine patch for approval in 2012 | NuPathe (NASDAQ: PATH) said it will resubmit a new drug application for its transdermal migraine patch for approval by the U.S. Food and Drug Administration after receiving a complete response letter from the regulator, according to the com... |
| - | New Pittsburgh venture fund eyes Cleveland location | A newly created venture capital fund from Pittsburgh may be coming to Northeast Ohio — if it can hit its fundraising goal.
Corridor Venture Partners is in the process of raising capital for its first fund, and is targeting Cleveland due to ... |
